Labopharm seeking FDA dispute resolution

Labopharm says it is seeking formal FDA dispute resolution proceedings to counter an approvable letter from the agency requiring undisclosed additional work on its NDA for a once-daily formulation of the pain-reliever tramadol.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions